Navigation Links
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Date:1/9/2008

nd Drug Administration (FDA) and has been designated an orphan medicinal product by the European Medicines Agency (EMEA) for the treatment of Hodgkin lymphoma.

About Vidaza

In May 2004, Vidaza became the first drug approved by the FDA for the treatment of patients with Myelodysplastic Syndromes (MDS). The FDA approved Vidaza, the first in a new class of drugs called demethylation agents, for treatment of all five MDS subtypes. These subtypes include: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

Vidaza is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of Vidaza required for maximum inhibition of DNA methylation in vitro does not cause major suppression of DNA synthesis. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. The cytotoxic effects of Vidaza cause the death of rapidly dividing cells, including cancer cells that are no longer responsive to normal growth control mechanisms. Non- proliferating cells are relatively insensitive to Vidaza. Vidaza was approved for IV administration in January 2007.

About Epigenetic Therapy

DNA methylation and histone deacetylation are the two most studied epigenetic regulators of gene expression. Vidaza reverses the effects of DNA hypermethylation with subsequent tumor suppressor gene re-expression. MGCD0103 exerts its epigenetic effects by acting as an oral isotype-selective HDAC inhibitor. Together, the two act synergistically to induce suppressor gene re-expression and favorably influence the clinical course of cancer. Pharmion strongly believes that by
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
5. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 Astellas announced today it ... Communications & Advocacy, Urology in the Americas. Noland will ... Advocacy Margaret Long. In this role, Noland will be ... patient and advocacy organizations, as well as collaborating ... initiatives. Noland,s appointment is the latest phase in ...
(Date:9/16/2014)... 2014 /PRNewswire-iReach/ -- Dan York has been ... of the RTD ® Advanced Wound Care Dressing, ... sales presence in the U.S. Under York,s leadership, GWM ... field sales representatives in new sales territories that will ... add up to 20 sales representatives in major metropolitan ...
(Date:9/16/2014)... DIEGO , Sept. 16, 2014  Denovo ... enzastaurin, a late-stage oncology drug, from Eli Lilly ... to develop, manufacture and commercialize enzastaurin globally, including ... data, and information. Lilly developed ... Phase 2 and Phase 3 clinical trials for ...
Breaking Medicine Technology:Christy Noland to Lead Urology Advocacy and Communications for Astellas 2GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2
... 2011 Reportlinker.com announces that a new market research ... Gastric Cancer Drug Discoveries: what the future holds ... Original analysis of the clinical potential ... candidates put into current market context Original ...
... 2011 Reportlinker.com announces that a new market research report ... Stent Market Outlook to 2016 http://www.reportlinker.com/p0483600/The-Drug-Eluting-Stent-Market-Outlook-to-2016.html ... DES market has seen tremendous growth since the introduction of ... on the release of clinical data that indicated a link ...
Cached Medicine Technology:Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 2Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 3Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 4Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 5Reportlinker Adds the Drug-Eluting Stent Market Outlook to 2016 2Reportlinker Adds the Drug-Eluting Stent Market Outlook to 2016 3Reportlinker Adds the Drug-Eluting Stent Market Outlook to 2016 4
(Date:9/16/2014)... 2014 Keep that sexy decolletage as you ... neck. , "The Face Whisperer Neck & Decollete Cream ... Heshelow, founder of Sublime Beauty®. "It contains rich ingredients to ... and arnica." , A special ingredient is Argireline, known as ... rich anti-aging cream comes in an airless pump bottle, and ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Today, ... published new information on transitioning employees to individual ... with the Affordable Care Act (ACA) in full ... be steering some or all of their employees ... surprise. With guaranteed issue plans, coverage for pre-existing ...
(Date:9/16/2014)... the well-known wedding dress manufacturer and retailer, has unveiled ... Additionally, the firm has launched a promotion for its ... up to 62 percent off. , All ... won a lot of positive reviews for its high-quality ... big savings on many other items, including corset bridesmaid ...
(Date:9/16/2014)... 16th, 2014; San Francisco) In a healthcare ... weighed against potential benefit, a Yale study has ... less-aggressive radiation procedures on elderly women with early-stage ... presented at the 56th annual conference of the ... (Abstract 131: Evaluating National Practice in Radiotherapy for ...
(Date:9/16/2014)... Recently, iFitDress.com, one of the most famous dress suppliers ... evening gown collection. According to the company’s sales manager, ... (up to 69% off) at present. Additionally, all the company’s ... am a frequent caller of your site. I like your ... feel quite happy. All items are of good quality. I ...
Breaking Medicine News(10 mins):Health News:15% Off Face Whisperer® Neck & Decollete Cream Now from Sublime Beauty; Care For This Delicate Skin That Shows Age Quickly 2Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2Health News:New Elegant Evening Wear Assortment Released By UWDress.com 2Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2
... a 60-cm-long sword that had been thrust through the nose ... ear, news reports said Wednesday. ,Ronnachai Tiemsanguan, 16, ... sword's removal from his face in an operation that took ... newspaper. ,Ronnachai received his sword wound Saturday when ...
... in the field of conducting tasks that involve spatial ... light turns green. , Researcher Eric Schumacher, ... Technology and colleagues, were surprised when they conducted MRI ... ,The researchers were testing the notion that areas ...
... suggests that ovarian cancer cells form by hijacking a ... Scientists at the Georgia Institute of Technology and the ... involved in the development of fallopian tubes and is ... ovarian tissue. The discovery not only provides a new ...
... Barbara, California – March 6, 2007 -- A team ... Berkeley and StrataGent// Life Sciences, of Los Gatos, California, ... to deliver protein drugs into the skin without the ... The research was published online today in the Proceedings ...
... It's already been established that type 2 diabetes increases the ... also a link between type 1 diabetes and this type ... but still, those with type 1 diabetes have a likelihood ... in non-diabetics. This is similar to the risk those with ...
... International Narcotics Control Board (INCB) – an independent body ... control// standards – is calling for the danger of ... ,In its annual report, the Vienna-based organisation ... drugs are not illegally manufactured or diverted from authorised ...
Cached Medicine News:Health News:Same Areas of the Brain Prepare for and Respond to a Stimulus, Say Experts 2Health News:Ovarian Cancer May Mimic Fallopian Tube Formation 2Health News:Ovarian Cancer May Mimic Fallopian Tube Formation 3Health News:Researchers Design Pulsed Mircrojet System to Deliver Protein Drugs Without Pain or Bruising 2Health News:Flood of Fake Drugs Must Be Stopped, Warns UN 2
... The RapidPCP test is an immunochromatography ... It is,designed for qualitative determination of ... cut-off level of 25 ng/mL. This ... the point of care location,and is ...
... Rapid Opiate II Rapid Opiates is an ... is designed for qualitative determination of Opiates ... presence of morphine in human urine above ... This assay has not been evaluated in ...
... All of DOA Panel ... one step in vitro test. ... of drug substances in human ... not,been evaluated in the point ...
... an immunochromatography based one step in vitro ... THC and its metabolites in human urine,specimens. ... urine above a cut-off,level of 50 ng/mL ... been evaluated in the point of care,location ...
Medicine Products: